biomed
research
recombin
poxvirus
investig
import
candid
medicin
deriv
advanc
option
prevent
andor
treatment
infecti
diseas
cancer
genet
engin
virus
readili
synthes
biolog
activ
heterolog
protein
serv
determin
relev
target
cellmedi
humor
immun
identifi
type
immun
respons
need
protect
multitud
differ
specif
diseas
substanti
progress
vaccin
develop
base
avail
except
safe
effici
carrier
virus
increasingli
versatil
vector
technolog
feasibl
larg
scale
manufactur
moreov
advanc
deciph
molecular
pathway
regul
poxvirushost
interact
provid
addit
mean
potent
activ
innat
immun
stimul
upon
vaccin
deriv
vector
specif
target
replic
capac
experiment
tumor
therapi
poxvirus
engin
express
foreign
gene
establish
extrem
valuabl
tool
modern
biotechnolog
vaccin
develop
medic
veterinari
research
review
see
compar
current
market
vaccin
viral
vector
appear
still
futurist
option
vaccin
develop
yet
mani
today
health
problem
vaccin
believ
becom
key
medicin
like
solv
exist
technolog
adequ
biolog
clinic
safeti
larg
packag
capac
recombin
dna
precis
virusspecif
control
target
gene
express
highlevel
immunogen
lack
persist
genom
integr
host
eas
vector
vaccin
product
import
featur
support
use
recombin
poxvirus
advanc
tool
immun
make
multival
poxviru
vector
vaccin
propos
particularli
desir
medicin
product
recombin
poxvirus
primarili
investig
novel
vaccin
major
human
anim
diseas
still
lack
effect
intervent
strategi
major
achiev
applic
vector
virus
provid
extraordinari
level
safeti
regard
protect
nontarget
environ
use
possibl
immunocompromis
target
popul
review
see
substanti
recent
progress
conduct
clinic
research
candid
vaccin
aid
tuberculosi
malaria
tumor
diseas
may
serv
exampl
poxvirus
engin
vector
vaccin
includ
virus
multipl
genera
orthopoxviru
vaccinia
viru
vacv
avipoxvirus
first
frequent
develop
applic
human
veterinari
medicin
promis
candid
vaccin
anim
diseas
deriv
parapox
suipox
capripox
leporipoxvirus
review
attempt
provid
updat
stateoftheart
poxviru
vector
technolog
sum
recent
progress
develop
prophylact
therapeut
recombin
vaccin
poxvirus
replic
within
cytoplasm
infect
cell
therefor
genom
transcrib
cellular
enzym
viru
encod
transcript
replic
machineri
dna
infecti
current
frequent
practic
strategi
gener
recombin
poxvirus
employ
homolog
dna
recombin
infect
cell
rel
frequent
event
poxvir
replic
recombin
typic
direct
plasmidbas
transfer
vector
contain
follow
featur
express
cassett
includ
poxvirusspecif
promot
usual
follow
multipl
clone
site
allow
insert
foreign
gene
choic
addit
select
screen
procedur
quit
use
eas
clonal
isol
recombin
virus
plaqu
purif
requir
addit
insert
select
marker
gene
express
cassett
heterolog
dna
sequenc
flank
poxviru
dna
sequenc
direct
recombin
desir
locu
nonessenti
region
poxvir
genom
fig
standard
insert
locu
gener
recombin
vacv
thymidin
kinas
tk
locu
allow
select
recombin
viru
tkneg
phenotyp
due
insert
inactiv
tk
tkdefici
cell
recent
improv
domin
neg
select
procedur
develop
recombin
vacv
insert
e
coli
tkthymidyl
kinas
tktmk
fusion
gene
convert
azt
toxic
compound
use
construct
recombin
inactiv
tktmk
gene
insert
transfer
vector
conveni
allow
select
azt
without
requir
use
tkdefici
cell
altern
transfer
vector
contain
antibiot
select
marker
report
gene
allow
screen
due
chang
phenotyp
coexpress
e
coli
galactosidas
glucuronidas
among
coexpress
antibiot
e
coli
gpt
gene
encod
enzym
xanthin
guanin
phosphoribosyl
transferas
frequent
use
stain
procedur
requir
addit
time
tissu
cultur
supplement
agar
overlay
use
chromogen
substrat
antibiot
complement
defect
viru
product
faster
conveni
method
obtain
recombin
virus
first
growth
select
protocol
initi
use
vacv
host
rang
gene
rescu
mutant
vacv
replic
rabbit
kidney
cell
blasco
colleagu
introduc
select
plaqu
format
coinsert
gene
vacv
mutant
appropri
complement
cell
line
enabl
growth
select
base
essenti
gene
function
transient
introduct
gene
genom
sever
growthrestrict
modifi
vacv
ankara
mva
use
simpl
effici
select
recombin
mva
coexpress
also
complement
defect
mva
life
cycl
cell
larg
size
coval
close
hairpin
end
dsdna
poxviru
genom
major
hurdl
direct
vitro
clone
recombin
virus
addit
sinc
poxvir
dna
infecti
isol
poxviru
genom
requir
helper
poxviru
suppli
essenti
enzym
need
initi
transcript
replic
recombin
viru
helper
viru
recombin
vector
viru
produc
infecti
progeni
cell
use
gener
recombin
viru
avian
poxvirus
leporipoxvirus
fulfil
requir
reactiv
recombin
vacv
one
approach
uniqu
restrict
site
introduc
vacv
genom
genom
clone
two
halv
lambda
phage
relig
two
halv
togeth
recombin
gene
direct
transfect
helper
virusinfect
cell
allow
gener
recombin
poxvirus
without
clone
intermedi
dna
construct
e
coli
moreov
effici
gener
reactiv
recombin
vacv
cell
transfect
clone
dna
also
enabl
construct
cdna
librari
anoth
eleg
method
engin
poxviru
vector
pioneer
recent
entir
vacv
genom
clone
bacteri
artifici
chromosom
bac
engin
e
coli
homolog
recombin
bacteriophag
lambdaderiv
enzym
modifi
bac
clone
use
produc
pure
recombin
poxviru
mammalian
cell
initi
assist
helper
viru
without
requir
plaqu
purif
anim
model
major
viral
diseas
influenza
hepat
b
rabi
serv
provid
first
strong
proofofprincipl
protect
prophylact
vaccin
recombin
poxviru
vaccin
prevent
diseas
human
reason
good
safe
vaccin
avail
certainli
contribut
delay
pharmaceut
develop
poxviru
vector
medic
applic
contrast
multipl
poxviru
vector
vaccin
alreadi
use
veterinari
medicin
licens
product
europ
includ
vaccin
base
recombin
vacv
recombin
canarypox
viru
prevent
rabi
equin
influenza
felin
leukemia
moreov
steadili
increas
interest
deriv
test
new
vector
vaccin
make
veterinari
medicin
import
drive
forc
develop
advanc
medicin
product
medic
research
develop
ongo
effort
focu
studi
candid
vector
vaccin
human
diseas
difficult
prevent
eg
caus
newli
emerg
chronic
viru
infect
bacteri
infect
parasit
cancer
overview
see
tab
safe
effect
human
immunodefici
viru
hiv
vaccin
urgent
need
control
worldwid
hiv
epidem
howev
develop
vaccin
aid
repres
substanti
scientif
challeng
relat
hiv
antigen
variabl
lack
understand
immun
correl
protect
limit
avail
anim
model
enorm
constraint
associ
probabl
need
multipl
largescal
clinic
trial
differ
part
world
review
see
moreov
fragil
immun
system
hivinfect
individu
set
high
standard
candid
vaccin
safeti
recent
highli
attenu
poxvirus
continu
play
major
role
intern
search
aid
vaccin
also
take
advantag
establish
technolog
vector
vaccin
product
industri
scale
exampl
safeti
howev
hiv
extraordinari
genet
divers
holi
grail
aid
vaccin
would
crossprotect
differ
hiv
clade
major
scientif
challeng
find
appropri
antigen
epitop
elicit
crossprotect
immun
respons
time
induct
cellular
immun
primari
focu
hiv
vaccin
develop
gener
broadli
neutral
antibodi
also
believ
indispens
concurr
data
two
studi
macaqu
model
show
booster
vaccin
oligomer
nativ
env
protein
enhanc
envbind
virusneutr
antibodi
respons
prime
recombin
mva
vaccin
suggest
antibodi
inde
like
play
role
vaccineinduc
protect
hepat
c
anoth
global
health
problem
caus
chronic
viru
infect
still
lack
prevent
vaccin
substanti
effort
current
dedic
preclin
research
anim
model
system
immunogen
first
poxviru
vector
vaccin
base
recombin
canarypox
viru
recombin
mva
test
hlatransgen
mous
model
threaten
episod
suddenli
emerg
coronaviru
infect
human
caus
sever
acut
respiratori
syndrom
impress
demonstr
suitabl
recombin
poxviru
vaccin
quickli
evalu
candid
vaccin
previous
unknown
pathogen
thu
view
current
struggl
tuneup
well
establish
rather
simpl
vaccin
technolog
prepar
global
threat
influenza
pandem
tempt
look
possibl
use
poxviru
vector
develop
potent
third
gener
influenza
virusspecif
vaccin
addit
recombin
poxvirus
proven
excel
aspir
vaccin
develop
disastr
infecti
diseas
global
impact
tuberculosi
malaria
review
see
incid
diseas
caus
mycobacterium
tuberculosi
steadili
increas
often
basi
povertyimpair
health
servic
widespread
hiv
infect
emerg
resist
tuberculosi
recent
effort
elicit
potent
antimycobacteri
immun
mva
vector
virus
serv
identifi
new
promis
target
antigen
result
develop
first
subunit
vaccin
enter
clinic
test
similarli
effect
vaccin
malaria
urgent
requir
varieti
antigen
plasmodium
falciparum
express
test
recombin
vacv
avipoxvirus
first
clinic
trial
initi
use
recombin
mva
fowlpox
viru
vector
suggest
use
primeboost
protocol
elicit
enhanc
malariaspecif
cell
immun
hivinfect
patient
therapeut
immun
consid
possibl
mean
achiev
viral
contain
without
mainten
antiretrovir
treatment
first
data
clinic
evalu
recombin
canarypox
viru
recombin
mva
vaccin
encourag
effici
expans
vaccinestimul
hiv
antigenspecif
andor
cell
respons
first
evid
improv
viru
control
identif
tumorassoci
antigen
taa
display
mhc
molecul
recogn
specif
cell
show
vaccin
might
serv
effect
therapi
number
malign
particular
potenti
activ
robust
cellular
mhc
class
iand
iirestrict
cell
respons
recombin
antigen
make
poxviru
vector
attract
vaccin
immunotherapeut
approach
cancer
experiment
cancer
therapi
viru
antigenassoci
malign
seem
predestin
target
vaccin
taa
consist
nonself
antigen
requir
break
immunotoler
taylor
cowork
demonstr
immunogen
epsteinbarr
viru
ebv
associ
nasopharyng
carcinoma
vaccin
reactiv
ebvspecif
memori
cell
vitro
evid
therapeut
efficaci
poxviru
vaccin
deliv
human
papillomaviru
hpv
antigen
cervic
cancer
associ
hpv
infect
phase
iii
clinic
trial
sever
poxviru
vaccin
candid
direct
autotaa
also
preclin
clinic
develop
use
carcinoembryon
antigen
cea
prostatespecif
antigen
psa
number
melanomaassoci
antigen
like
tyrosinas
melana
furthest
develop
vaccin
strategi
summar
kwak
et
al
often
strategi
combin
either
cytokin
like
costimulatori
molecul
blockad
cellular
adjuv
like
dendrit
cell
enhanc
immun
respons
antigen
like
tolerogen
self
protein
one
approach
experiment
cancer
therapi
base
oncolyt
virus
ov
select
engin
replic
propag
spread
exclus
tumor
cell
lead
destruct
affect
normal
cell
target
possibl
ov
exploit
cellular
defect
permit
tumor
cell
growth
date
sever
type
ov
develop
enter
clinic
trial
trial
demonstr
accept
safeti
profil
ov
limit
therapeut
efficaci
use
monotherapi
howev
improv
perform
note
ov
use
combin
tradit
therapi
chemotherapi
radiat
review
replic
vacv
develop
oncolyt
agent
review
see
abl
infect
spread
larg
varieti
cell
confer
antitumor
effect
virusmedi
cell
death
first
phase
clinic
trial
vacv
recombin
express
granulocytemacrophag
colonystimul
factor
gmcsf
appli
intratumor
show
vector
well
toler
effici
limit
extent
treatment
cutan
melanoma
vacv
variant
engin
improv
safeti
caus
ineffici
replic
normal
cell
retain
high
propag
effici
tumor
cell
delet
tk
vaccinia
growth
factor
vgf
gene
shown
decreas
vacv
virul
tkvgfneg
vacv
doubl
mutant
attenu
show
enhanc
growth
capac
tumor
cell
preferenti
replic
tumor
cell
attribut
requir
ttp
dna
synthesi
nucleotid
pool
present
highli
divid
cell
activ
epiderm
growth
factor
receptor
egfr
signal
pathway
frequent
abnorm
cancer
cell
anoth
attenu
strategi
make
use
abil
cancer
cell
evad
induct
apoptosi
addit
delet
viral
antiapoptot
gene
vacv
genom
result
recombin
vacv
preferenti
replic
transform
cell
display
signific
antitumor
effect
mous
model
rabbit
poxviru
myxoma
viru
mv
caus
myxomatosi
european
rabbit
nonpathogen
man
also
develop
oncolyt
viru
candid
mv
encod
protein
counteract
rabbit
interferon
unabl
antagon
interferon
speci
includ
human
normal
interferonrespons
human
cell
mv
replic
block
howev
mv
product
infect
varieti
human
tumor
cell
nonrespons
interferon
sinc
viru
infect
man
preexist
immun
human
popul
togeth
appar
inher
tropism
human
tumor
cell
suggest
potenti
exploit
mv
novel
ov
platform
live
poxvir
vector
particularli
attract
mimic
natur
infect
allow
de
novo
synthesi
heterolog
vaccin
antigen
herebi
poxvir
vector
vaccin
expect
elicit
appropri
danger
signal
immun
system
result
preferenti
recognit
present
target
antigen
concern
safeti
poxvirus
includ
vacv
former
vaccin
success
use
erad
human
smallpox
address
applic
virus
replic
defect
avirul
test
vivo
date
multipl
type
poxviru
vector
develop
enter
clinic
trial
particularli
area
hivaid
cancer
vaccin
develop
mani
result
suggest
satisfi
safeti
efficaci
poxviru
vector
vaccin
regard
elicit
specif
immun
respons
select
target
antigen
human
nevertheless
complex
involv
induc
protect
immun
infect
immunodefici
virus
elicit
potent
immun
respons
tumourassoci
selfantigen
suggest
immunogen
candid
vaccin
may
still
need
booster
achiev
protect
vaccin
aid
malaria
cancer
herebi
excit
recent
result
basic
poxviru
research
help
reveal
astonish
versatil
poxvir
strategi
counteract
innat
host
immun
respons
lead
gener
optim
vector
even
better
poxviru
vaccin
